Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
The new lineup includes CereTom Elite, OmniTom Elite, OmniTom Elite PCD, and BodyTom 32/64
The company has improved access to quality healthcare for seniors across both urban and rural areas
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Phase 1 dosing is expected to finish by the end of 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
Subscribe To Our Newsletter & Stay Updated